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S.J. Crutch et al. / Alzheimer’s & Dementia- (2017) 1-152Abstract Introduction: A classification framework for posterior cortical atrophy (PCA) is proposed to
improve the uniformity of definition of the syndrome in a variety of research settings.
Methods: Consensus statements about PCAwere developed through a detailed literature review, the
formation of an international multidisciplinary working party which convened on four occasions, and
a Web-based quantitative survey regarding symptom frequency and the conceptualization of PCA.
Results: A three-level classification framework for PCA is described comprising both syndrome-
and disease-level descriptions. Classification level 1 (PCA) defines the core clinical, cognitive, and
neuroimaging features and exclusion criteria of the clinico-radiological syndrome. Classification
level 2 (PCA-pure, PCA-plus) establishes whether, in addition to the core PCA syndrome, the core
features of any other neurodegenerative syndromes are present. Classification level 3 (PCA attribut-
able to AD [PCA-AD], Lewy body disease [PCA-LBD], corticobasal degeneration [PCA-CBD],
prion disease [PCA-prion]) provides a more formal determination of the underlying cause of the
PCA syndrome, based on available pathophysiological biomarker evidence. The issue of additional
syndrome-level descriptors is discussed in relation to the challenges of defining stages of syndrome
severity and characterizing phenotypic heterogeneity within the PCA spectrum.
Discussion: There was strong agreement regarding the definition of the core clinico-radiological
syndrome, meaning that the current consensus statement should be regarded as a refinement, devel-
opment, and extension of previous single-center PCA criteria rather than any wholesale alteration or
redescription of the syndrome. The framework and terminology may facilitate the interpretation of
research data across studies, be applicable across a broad range of research scenarios (e.g., behavioral
interventions, pharmacological trials), and provide a foundation for future collaborative work.
 2017 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Keywords: Posterior cortical atrophy; Alzheimer’s disease; Clinico-radiological syndrome; Pathophysiology; Biomarker1. Introduction
The term posterior cortical atrophy (PCA) was coined by
D. Frank Benson and colleagues to describe a series of pa-
tients with early visual dysfunction in the setting of neurode-
generation of posterior cortical regions [1] (Fig. 1). The PCA
syndrome aligned with several other reports of patients
with similar progressive loss of higher visual function
(e.g., [3–13]). PCA typically presents in the mid-50s or early
60s with a variety of unusual visuoperceptual symptoms,
such as diminished ability to interpret, locate, or reach for
objects under visual guidance; deficits in numeracy, literacy,
and praxis may also be apparent. Although episodic memory
and insight are initially relatively preserved, progression of
PCA ultimately leads to a more diffuse pattern of cognitive
dysfunction.
Several single-center groups of researchers have proposed
diagnostic criteria for the syndrome [14,15] or detailed
inclusion criteria for individual studies (e.g., [16–18]).
PCA has also been recognized and described in consensus
criteria for typical and atypical Alzheimer’s disease
[19,20]. These existing criteria have reasonable consistency
and have proved useful in many clinical and research
contexts.
However, the extant detailed descriptions of PCA are
based on clinical experience at single centers and have not
been deliberated or validated more widely. Present-day
PCA criteria were also formulated before the development
of Alzheimer’s disease (AD) pathophysiological bio-
markers, and although recent AD criteria include PCA, theclinical phenotype is not described in detail and such criteria
naturally do not encompass individuals with the PCA syn-
drome who are negative for AD pathophysiological bio-
markers. Some inconsistencies exist among the core
features described, with the Tang-Wai but not Mendez
criteria excluding individuals with early Parkinsonism or
hallucinations, while Mendez but not Tang-Wai stipulates
the relative preservation of verbal fluency [14,15]. Such
inconsistencies are mirrored explicitly or implicitly in the
application of terminology, with the term PCA sometimes
being used as a descriptive clinical (syndrome level) term
and sometimes as a diagnostic (disease level) label. For
example, some researchers consider PCA primarily or
solely as an atypical form of AD (the “visual variant of
AD,” e.g., [21]), whereas others cite neuropathological evi-
dence demonstrating that multiple pathologies can underlie
the PCA syndrome (e.g., [16]). Inconsistency of terminology
and usage likely reflects in part the interests or requirements
of different investigators or research contexts. For example,
syndromic classification is likely to be entirely appropriate
for studies exploring behavioral interventions, whereas clin-
ical trials of disease-specific pharmacological agents may
additionally require consideration of the underlying molec-
ular pathology. In the absence of criteria that clearly reflect
this potential diversity of use, it remains unclear whether
individuals with PCA should be included or excluded from
conventional clinical trials for AD (e.g., owing to the poten-
tial unsuitability of the associated interventions, biomarkers,
and/or outcome measures). Consequently, individuals
Fig. 1. Single-participant axial images for one control participant and one patient with PCA showing cerebral blood flow (ASL), glucosemetabolism (FDG-PET),
atrophy (structural magnetic resonance imaging), and amyloid deposition (florbetapir-PET). For clinical purposes, 18F-florbetapir images should be read on a gray
scale. Abbreviations: ASL, arterial spin labeling; CBF, cerebral blood flow; FDG-PET, 18F-labeled fluorodeoxyglucose positron emission tomography; PCA, pos-
terior cortical atrophy; SUVR, standard uptake value ratio. For tau deposition data see Ossenkoppele et al [2]. Adapted from Lehmann et al., 2016, Figure 1.
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ful interventions owing to a lack of evidence regarding their
effectiveness. Conversely, if criteria require evidence for AD
pathology, individuals with PCA due to other causes may not
be considered for behavioral interventional trials fromwhich
they may benefit. Finally, existing criteria provide an inade-
quate foundation from which to proceed with future studies
exploring the factors influencing phenotypic heterogeneity
and disease progression, acquiring evidence linking clinical
phenotype to underlying pathology.
2. Aims
The present study describes the formation and delibera-
tions of a PCA working party that aimed to establish a
consensus opinion regarding the PCA syndrome. The goal
of the work was to review, revise, and complement existing
single-center diagnostic criteria to represent multidisci-
plinary and multicenter experience and knowledge. In lightof the problems outlined previously and the challenges fac-
ing the PCA research field, a multilevel PCA classification
framework is proposed for use in a number of different
research contexts.
3. Methods
Following a detailed review of the literature (S.J.C., M.L.,
J.M.S., G.D.R., M.N.R., and N.C.F. [22]), a PCA Working
Party of experienced clinicians and researchers formed to
develop a consensus statement regarding research criteria
for PCA. Representatives of the group met at the Alz-
heimer’s Association International Conferences in Vancou-
ver (July 2012; see [23]) and Boston (July 2013). An
Atypical Alzheimer’s Disease and Associated Disorders Pro-
fessional Interest Area (PIA) was subsequently constituted
subsequently under the auspices of the International Society
to Advance Alzheimer’s Research and Treatment. In June
2014, an online survey of Working Party and PIA members
S.J. Crutch et al. / Alzheimer’s & Dementia- (2017) 1-154was conducted. Participants were requested to estimate the
frequency of symptoms, signs, and features (never seen
[0%], rare [0%–25%], common [25%–75%], very frequent
[75%–100%], always present [100%]). Participants were
also asked to rate their level of agreement with a series of
statements regarding the conceptualization of PCA (Likert
scale: 15 strongly disagree, through to 75 strongly agree).
The survey was completed by 36 experienced group mem-
bers with backgrounds in neurology, psychology, pathology,
psychiatry, gerontology, and neuroscience (years since
qualification: mode and median: 20–30 years, range:
1–.30 years; number of individuals with PCA encountered:
median: 20–30, mode: 30–50, range: 1–.50). The results of
the survey (see Fig. 2) and their implications for a consensus
statement were discussed at the next PIA meeting (AAIC,
Copenhagen, July 2014). The consensus statement was sub-
sequently drafted (S.J.C.) and developed with a small group
of experts (N.C.F., J.M.S., G.D.R., W.M.v.d.F., M.M.,
B.C.D., R.V., and J.S.S.), and a revised version circulated
to the PCA Working Party and selected PIA members for
their detailed feedback before final discussion and agree-
ment (AAIC, Washington, July 2015). The final version
was approved by all authors.4. Classification framework
A three-level classification framework for PCA is
described in Fig. 3. Level 1 establishes that the presenting
problem has a neurodegenerative basis and a posterior
cortical focus, based on the identification of the core clinical
and cognitive features that define the PCA syndrome, plus
supportive neuroimaging evidence if available. Further
core features include evidence of insidious onset and gradual
progression. Exclusion criteria include evidence of a brain
tumor or other mass lesion, significant vascular disease
including focal stroke, primary ocular disease, or other iden-
tifiable causes for cognitive impairment, but only where
independently sufficient to explain the clinical and cognitive
syndrome. Level 2 establishes whether the presentation is
one of pure PCA or whether the patient meets the core
criteria for both the PCA syndrome and an additional neuro-
degenerative syndrome (in the absence of biomarkers). Level
3 involves a more formal determination of the underlying
cause of the PCA syndrome, based on pathophysiological
biomarker evidence. Levels 1 and 2 yield a syndrome-level
description of the presenting complaint. Level 3 yields a
disease-level description. Levels 1–3 are outlined in greater
detail in the following.4.1. Classification level 1: The core features of the PCA
syndrome
As defined in the perspective article which followed the
first consensus meeting, “PCA is a clinico-radiological syn-
drome characterized by progressive decline in visual pro-
cessing and other posterior cognitive functions, relativelyintact memory and language in the early stages, and atrophy
of posterior brain regions” ([24], p. 463). The core clinical,
cognitive, and (optional supportive) neuroimaging features
and exclusion criteria for PCA are listed in Table 1. These
early or presenting features are listed in order of (descend-
ing) frequency at first assessment in line with the quantita-
tive ratings provided by online survey participants (see
Fig. 2). The list of cognitive features is a summation of all
features listed in Mendez et al. [14] and Tang-Wai et al. [15].
The clinical and exclusion criteria constrain the definition
of PCA to individuals with a neurodegenerative condition.
The semi-arbitrary stipulation of three or more cognitive fea-
tures is designed to ascertain evidence of a cluster of poste-
rior cognitive deficits and reduce misclassifications based on
overinterpretation of a single complaint or abnormal test
score. The stringency of this stipulation is also mitigated
by the extensive list of potential features which fall broadly
into the domains of basic visual, visuoperceptual, visuospa-
tial, literacy, numeracy, praxis, and higher sensory functions.
Many of these posterior cognitive deficits may have a pro-
nounced impact on activities of daily living.
A critical element of the PCA cognitive profile is the
contrast between the posterior cortical dysfunction and the
relative sparing of other cognitive domains. This is aimed
at distinguishing PCA from typical (amnestic) AD (episodic
memory), logopenic-variant primary progressive aphasia
(lvPPA; language), frontotemporal dementia and the AD
phenotype variously labeled frontal variant AD, behavioral
variant AD, or dysexecutive AD (which primarily manifests
as impairments of executive functions, behavior, and person-
ality). The concept of “relative sparing” is intentionally flex-
ible to accommodate different assessment settings and tools.
Operationalizing these criteria with recommended sets of
brief and detailed cognitive tasks is a future objective of
the working group, but the main principle is to reduce the
impact of core deficits on assessment of these functions.
For example, accurate testing of anterogradememory in peo-
plewith PCA requires tests that avoid not only explicit visual
demands (e.g., Rey–Osterrieth figure copy) but alsomore im-
plicit visual demands on visually mediated processes such as
mental imagery (e.g., verbal paired associate learning).
The neuroimaging features of PCAare intentionally broad
to reflect the loose anatomical description of “posterior
cortical atrophy,” with theworking group regarding evidence
of focal structural (e.g., atrophy on magnetic resonance
imaging) or functional (e.g., hypometabolism on 18F-labeled
fluorodeoxyglucose positron emission tomography or single-
photon emission computed tomography) abnormality in the
occipital, parietal, and/or occipito-temporo-parietal cortices
as supportive of the clinico-radiological syndrome. The
inclusion of neuroimaging evidence of posterior cortical
atrophy or dysfunction as an optional, supportive feature
rather than obligatory component of the syndrome-level
description is consistent with previous criteria. This issue
generated considerable debate, but maintaining the optional
status was justified on both clinical (e.g., variable extent of
Fig. 2. Mean and standard error ratings of clinical presentation features, symptoms, and signs in PCA, as rated by experts in the online survey. Abbreviation:
PCA, posterior cortical atrophy.
S.J. Crutch et al. / Alzheimer’s & Dementia- (2017) 1-15 5
S.J. Crutch et al. / Alzheimer’s & Dementia- (2017) 1-156atrophy at presentation) and practical grounds (e.g., accessi-
bility of neuroimaging facilities; not wishing to exclude
patients unable to undergo M.R. investigation from all
PCA-related research). Where for practical reasons neuroi-
maging evidence cannot be obtained, research studies should
specify the evidence used to support the classification of
PCA. Another issue is that individuals with the visual variant
of Creutzfeldt–Jakob disease typically decline rapidly
such that obvious focal atrophy is not easily demonstrated
[25–27]. We debated the utility of classifying such
individuals within the PCA framework, which may only be
appropriate for prion disease patients with an insidious
(rather than rapid) progression ([16], subject [21,28]). It
should also be noted that evidence provided by more
recently established molecular imaging techniques is
incorporated together with other in vivo biomarkers in the
disease-level description (see classification level 3).
The clinical, cognitive, and exclusion criteria (discussion
of neuroimaging criteria mentioned previously) are largely
consistent with existing single-center definitions of the syn-
drome [14,15]. Working group discussions elicited broad
agreement regarding the specific features that constitute
PCA and there was a strong reluctance to radically alter
preceding descriptions of the syndrome, which has becomeFig. 3. Diagnostic process and PCA classification. Key diagnostic questions at
levels 1 and 2) are lightly shaded and disease-level descriptions (classification lev
and PCA-prion (solid ovals) are distinguished from PCA-LBD and PCA-CBD (d
biomarkers. Other disease-level classifications may be appropriate (e.g., a patient w
ipated (e.g., PCA attributable to GRNmutations). The thickness of lines connecting
common cause of PCA. Abbreviations: AD, Alzheimer’s disease; CBD, corticobas
tbc, to be confirmed.a well-established clinical concept. Nonetheless, one point
of note is the primacy given to visual impairment in the
earlier criteria (Mendez et al: “Presentation with visual com-
plaints with intact primary visual functions”; Tang-Wai et al:
“Presentation of visual complaints in the absence of signifi-
cant primary ocular disease explaining the symptoms”
[14,15]). In the proposed consensus statement, this
criterion is broadened to “Prominent early disturbance of
visual plus/minus other cognitive functions with a
presumed posterior location.” This reflects the position of
65% of the online survey group who agreed (compared
with 15% disagreeing and 20% neither agreeing nor
disagreeing) with the statement “Progressive focal
disorders of nonvisual posterior cognitive functions (e.g.,
apraxia, agraphia, acalculia) can also be classified as PCA
in some research contexts.” The working group rejected
further broadening of the criterion to “Prominent early
disturbance of visual and/or other posterior cognitive
functions” on the basis that (1) removal of the visual
criterion might lead to unhelpful diagnostic confusion
between PCA and corticobasal syndrome (CBS), lvPPA
and other syndromes, (2) very detailed neuropsychological
testing of patients presenting with focal posterior
nonvisual complaints typically uncover evidence of subtleeach level are shown in boxes. Syndrome-level descriptions (classification
el 3) are darkly shaded. Among the disease-level classifications, PCA-AD
ashed ovals) owing to the current availability of in vivo pathophysiological
ith PCA plus visual hallucinations may have LBD-variant of AD) or antic-
classification levels 2 and 3 is intended to reflect the status of AD as themost
al degeneration; LBD, Lewy body disease; PCA, posterior cortical atrophy;
Table 1
Core features of the PCA clinico-radiological syndrome (classification level 1)
Clinical, cognitive, and neuroimaging features are rank ordered in terms of (decreasing) frequency at first assessment as rated by online survey participants
(see Fig. 2)
Clinical features:
Insidious onset
Gradual progression
Prominent early disturbance of visual 6 other posterior cognitive functions
Cognitive features:
At least three of the following must be present as early or presenting features 6 evidence of their impact on activities of daily living:
Space perception deficit
Simultanagnosia
Object perception deficit
Constructional dyspraxia
Environmental agnosia
Oculomotor apraxia
Dressing apraxia
Optic ataxia
Alexia
Left/right disorientation
Acalculia
Limb apraxia (not limb-kinetic)
Apperceptive prosopagnosia
Agraphia
Homonymous visual field defect
Finger agnosia
All of the following must be evident:
Relatively spared anterograde memory function
Relatively spared speech and nonvisual language functions
Relatively spared executive functions
Relatively spared behavior and personality
Neuroimaging:
Predominant occipito-parietal or occipito-temporal atrophy/hypometabolism/hypoperfusion on MRI/FDG-PET/SPECT
Exclusion criteria:
Evidence of a brain tumor or other mass lesion sufficient to explain the symptoms
Evidence of significant vascular disease including focal stroke sufficient to explain the symptoms
Evidence of afferent visual cause (e.g., optic nerve, chiasm, or tract)
Evidence of other identifiable causes for cognitive impairment (e.g., renal failure)
Abbreviations: PCA, posterior cortical atrophy; MRI, magnetic resonance imaging; FDG-PET, 18F-labeled fluorodeoxyglucose positron emission tomog-
raphy; SPECT, single-photon emission computed tomography.
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“nonvisual” complaints may be partly rooted in visual
dysfunction (e.g., writing impairments partly attributable
to disordered mental imagery for letters).4.2. Classification level 2: Pure PCA and PCA with
additional features (PCA-plus)
In classification level 2, a division is drawn between indi-
viduals who solely meet the criteria for PCA (PCA-pure)
and individuals who exhibit additional features consistent
with other recognized neurodegenerative syndromes
(PCA-plus). All individuals must fulfill the criteria for the
core clinico-radiological syndrome (level 1), with the
PCA-pure/PCA-plus distinction made on the basis of
nonfulfillment/fulfillment of additional core clinical criteria
for lvPPA, CBS, or another neurodegenerative syndrome
(see Table 2). The cited examples are based on recognized
diagnostic criteria for the clinical syndromes of dementia
with Lewy bodies [29] and CBS [30,31].Classification level 2 exists as a buffer zone between a
broad, purely symptomatic definition of PCA (level 1) and
disease-level descriptions of the different clinico-biological
entities (supported by biomarker evidence) which fall under
that syndromic umbrella (level 3). This intermediate classifi-
cation stage is motivated by a combination of in vivo
biomarker and postmortem pathological data, clinical
opinion, and research practicality. In vivo biomarker and
postmortem pathological data from published case series
indicate that the vast majority of reported cases of PCA are
attributable to AD (see [15,16,32–34]). Reflecting such
data, clinical opinion has tended toward regarding PCA
primarily or even solely as an atypical phenotype of AD,
many defining PCA as “the visual posterior variant of AD.”
Accordingly, some working group members questioned
whether features suggestive of non-AD pathologies, such
as hallucinations and cognitive fluctuations suggestive of
the histopathologically defined entity of Lewy body disease
(LBD), should even be incorporated as exclusion criteria in
the core definition of PCA. The PCA-pure/PCA-plus
Fig. 4. Case study of a PCA patient presenting with “nonvisual” symptoms. Abbreviation: PCA, posterior cortical atrophy.
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inclusion to a subpopulation who may be more likely to
have AD as the underlying pathology, while at the sameTable 2
Classification of PCA-pure and PCA-plus (classification level 2)
PCA-pure
Individuals must fulfill the criteria for the core clinico-radiological PCA synd
neurodegenerative syndrome.
PCA-plus
Individuals must fulfill the criteria for the core clinico-radiological PCA synd
neurodegenerative syndrome, such as
Dementia with Lewy bodies (DLB)
Following the diagnostic criteria proposed by theDLB consortium (McKeith
A) or one or more core features (list A) and one or more suggestive feature
A. Core features
 Fluctuating cognition with pronounced variations in attention and
 Recurrent visual hallucinations that are typically well formed and
 Spontaneous features of parkinsonism
B. Suggestive features
 Rapid eye movement (REM) sleep behavior disorder
 Severe neuroleptic sensitivity
 Low dopamine transporter uptake in basal ganglia demonstrated b
Corticobasal syndrome (CBS)
Following the modified CBS criteria proposed by Armstrong et al. (2013),
a) limb rigidity or akinesia
b) limb dystonia
c) limb myoclonus
plus 2 of:
d) orobuccal or limb apraxia
e) cortical sensory deficit
f) alien limb phenomena (more than simple levitation)
Possible corticobasal syndrome may be symmetric and requires presentatio
Abbreviations: PCA, posterior cortical atrophy; SPECT, single-photon emissiotime acknowledging the lack of one-to-one correspondence
between syndrome and pathology (e.g., patients fulfilling
PCA and CBS criteria whose impairments are attributablerome (level 1), and not fulfill core clinical criteria for any other
rome (level 1) and also fulfill core clinical criteria for at least one other
et al., 2005), individualsmust exhibit two ormore core features of DLBs (list
s (list B):
alertness
detailed
y SPECT or PET imaging
a diagnosis of probable CBS requires asymmetric presentation of 2 of
n of 1 of a–c plus 1 of d–f.
n computed tomography; PET, positron emission tomography.
S.J. Crutch et al. / Alzheimer’s & Dementia- (2017) 1-15 9to AD). The PCA-plus classification may also capture indi-
viduals who show additional features owing tomixed pathol-
ogy or moderate to high subcortical vascular burden. Such
debate may be moot in most situations where in vivo bio-
markers are available. However, a full examination of the
relationship between the PCA phenotype and underlying pa-
thologywill require documentation of the fulfillment/nonful-
fillment of both core PCA and additional syndromic criteria.
There are also methodological limitations concerning bio-
markers reflected in variability of results across laboratories
[35,36]. Besides, molecular imaging and cerebrospinal fluid
analysis are not available for all individuals in all centers, and
pathophysiological biomarkers are available for a limited
number of diseases and it is only the diagnostic criteria for
AD and FTD incorporate them. Ultimately, the Working
Party aimed to produce consensus guidelines that have
utility in every research setting. Thus, the concepts PCA-
pure and PCA-plus are advanced as a simple, practicable
method for improving the consistency of inclusion criteria
in studies and refining PCA samples in situations where
biomarker data are not available. Also, International Work-
ing Group criteria (IWG2) [20] do not provide a formal clas-
sification for individuals with a clinical presentation
consistent with PCA in whom in vivo biomarkers are not
available. The intermediate classification of PCA-pure/
PCA-plus is aimed at facilitating the inclusion of participants
in research studies even in the absence of direct evidence of
underlying pathophysiological process. The practical impli-
cation of this formulation is that the concept of PCA-pure or
-plus (level 2)may be largely redundant where biomarker ev-
idence is available, where the expectation would be classifi-
cation at disease-specific level 3 (see the following).Table 3
Diagnostic criteria for disease-level descriptions (classification level 3)
PCA-AD
Following IWG2 (Dubois et al., 2014), the classification of PCA-AD (and, by e
of the PCA syndrome (classification level 1) plus in vivo evidence of Alzheim
 Decreased Ab1–42 together with increased T-tau and/or P-tau in CSF
 Increased tracer retention on amyloid PET
 Alzheimer’s disease autosomal-dominant mutation present (in PSEN1, P
If autopsy confirmation of AD is available, the term definite PCA-AD would
PCA-LBD
Molecular biomarkers for LBD are currently unavailable; therefore, an in vivo d
both classified as PCA-mixed by virtue of fulfilling DLB clinical criteria and
appropriate. If autopsy confirmation of LBD is available, the term definite PCA
appropriate for individuals with mixed or multiple pathologies (e.g., PCA-AD
PCA-CBD
Molecular biomarkers for CBD are currently unavailable; therefore, an in vivo d
both classified as PCA-mixed by virtue of fulfilling CBS criteria and shown to b
If autopsy confirmation of CBD is available, the term definite PCA-CBD wou
PCA-prion
There are a number of promising biomarkers for prion disease (e.g., Orru et a
incorporated into diagnostic criteria. Pending this process, an in vivo diagnosi
available or a known genetic form of prion disease has been determined, the t
Abbreviations: PCA, posterior cortical atrophy; AD, Alzheimer’s disease; IWG
disease; DLB, dementia with Lewy bodies; CBD, corticobasal degeneration; CBS4.3. Classification level 3: Diseases causing PCA
Classification level 3 provides disease-level descriptions
of PCA reflecting available evidence of the underlying pa-
thology. Diagnostic criteria for PCA attributable to AD
(PCA-AD), Lewy body disease (PCA-LBD), corticobasal
degeneration (PCA-CBD), and prion disease (PCA-prion)
are described in Table 3. The definition of PCA-AD is
consistent with the IWG2 [20,37,38] definitions of AD,
which require both the presence of an appropriate clinical
phenotype and a pathophysiological biomarker consistent
with the presence of AD pathology. However,
pathophysiological biomarkers are only currently available
for AD and prion disease (although not yet incorporated
into formal diagnostic criteria for prion disease; see solid
and dashed ovals in Fig. 3). Consequently, the disease-
level descriptions provided in Table 3 are inequitable, with
attribution of an in vivo diagnosis of PCA-LBD and PCA-
CBD pending the development of suitable biomarkers. In
these cases, use of the terms probable PCA-LBD and prob-
able PCA-CBD may be appropriate where cases fulfilling
both the relevant core clinical criteria are found to be nega-
tive for AD biomarkers. As noted in Fig. 3, other disease-
level classifications may also be appropriate for individuals
with mixed or multiple pathologies (e.g., a patient with PCA
plus visual hallucinations could have LBD-variant of AD
and therefore be more appropriately labeled PCA-AD/
LBD; co-occurrence of AD and PSP: [39]) or required in
future (e.g., PCA attributable to GRN mutations; [40]).
Similarly, additional markers may become available to sup-
port existing and new classifications. Future iterations of the
PCA consensus statement must consider these issues andxtension, of IWG2’s broader category of “atypical AD”) requires fulfillment
er’s pathology (at least one of the following):
SEN2, or APP)
be appropriate.
iagnosis of PCA-LBD cannot be assigned at present. For individuals who are
shown to be AD-biomarker negative, the term probable PCA-LBD may be
-LBD would be appropriate. Other disease-level classifications may also be
/LBD).
iagnosis of PCA-CBD cannot be assigned at present. For individuals who are
e AD-biomarker negative, the term probable PCA-CBDmay be appropriate.
ld be appropriate.
l., 2014; Jackson et al., 2014; McGuire et al., 2012), but these have yet to
s of PCA-prion may be feasible. If autopsy confirmation of prion disease is
erm definite PCA-prion would be appropriate.
2, International Working Group; CSF, cerebrospinal fluid; LBD, Lewy body
, corticobasal syndrome.
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development and emerging clinical reports.
The division between syndrome-level and disease-level
descriptions was supported by 88% of PCAWorking Party
members surveyed who agreed with the statement
“Research criteria should discriminate the clinical syndrome
(PCA) and the associated disease (e.g., PCA-AD, PCA-
LBD).” The discussion of the syndrome/disease issue at
consensus meetings reflected the balance sought between
developing a flexible labeling system allowing for a wide va-
riety of different research applications (e.g., disease-specific
trials vs. nonpharmacological interventions targeting cogni-
tion, behavior, or function) and avoiding confusion by
permitting a PCA subgroup (e.g., those fulfilling criteria
for PCA and CBS) to skew the description of PCA. It is
also important to note that the four proposed disease-level
descriptions do not have the same frequency. Published
data suggest that AD is overwhelmingly the most common
underlying cause of PCA (e.g., [15,16,32–34,41,42]).
Thus, in the absence of features to suggest an alternative
diagnosis, AD is a priori the most likely underlying cause.
The thickness of lines connecting classification levels 2
and 3 in Fig. 3 are intended to reflect the status of AD as
the most common cause of PCA. It is also noted that in all
cases, pathological confirmation of the underlying pathol-
ogy is regarded as the “gold standard” and assigned the pre-
fix definite.
There are a number of research contexts in which it may
be important to identify the most likely underlying pathol-
ogy associated with the PCA syndrome. The proposed
disease-level descriptions of PCA may be of use in
disease-specific clinical trials (by providing rationale the in-
clusion of PCA subjects in AD trials), in descriptive epide-
miological studies investigating genetic and other
determinants of phenotypic heterogeneity in AD and non-
AD dementias, and in disease progression studies.5. Further specification of PCA in a variety of research
contexts
The classification system described previously provides
syndrome-level and disease-level definitions of PCA for
use in a variety of research contexts. However, there are a
number of past and future contexts in which additional
consensus descriptors might have value. Two important sce-
narios are staging the syndrome severity and describing
phenotypic heterogeneity within PCA. In the following,
we discuss this need, alongside the current labels related to
PCA and their usage.We stop short of proposing an extended
PCA lexicon but explicate how future research might prompt
or guide a formal proposal of terms. All of the following sce-
narios consider the putative case of individuals who did, do,
or might fulfill the core PCA criteria described previously at
some point past, present, or future, plus the additional re-
quirements listed in the following.6. PCA stages
One issuewhichmaymotivate an extension of PCA termi-
nology concerns how researchers describe PCA at different
stages of progression. To illustrate the issue, 11-year longitu-
dinal data are presented on an individual who came to atten-
tion as a healthy research participant but subsequently
developed PCA (see Fig. 5). The description of this patient
at different points along the disease pathway is considered
in the following alongside consideration of provisional terms.
 Prodromal/suspected/possible PCA: This term (see al-
ternatives in the following) might be ascribed (in some
circumstances, alongside other differential diagnoses)
to individuals exhibiting subtle deficits in posterior
cortical functions which are too mild or few (,3) to
fulfill the core PCA criteria mentioned previously. As
only individuals proceeding to a diagnosis of PCA
could reliably be labeled prodromal PCA, this stage
in the evolution of PCAwould most likely be identified
retrospectively in longitudinal studies (see Fig. 5). In
other situations, alternative labels such as “suspected
PCA” or “possible PCA” might be preferred. The
concept of prodromal PCA is motivated by the assump-
tion that a proportion of individuals with prodromal
AD (IWG criteria; 37; clinical symptoms present but
insufficient to affect instrumental activities of daily
living) will be in the early clinical stages of PCA. By
definition, the clinico-radiological syndrome PCA
cannot be defined at the preclinical asymptomatic at-
risk state for AD (IWG [38]) or stage 1 or 2 preclinical
AD (NIA-AA [44]) where cognitive impairment is
absent. It is also of note here that some individuals
with PCA may not ever meet NIA-AA definitions of
mild cognitive impairment (MCI), owing to the impact
of even subtle posterior cortical dysfunction on
everyday functional tasks. MCI criteria state “These
cognitive changes should be sufficiently mild that there
is no evidence of a significant impairment in social or
occupational functioning” (p. 272), and “it must be
recognized that atypical clinical presentations of AD
may arise, such as the visual variant of AD (involving
PCA) or the language variant (sometimes called logo-
penic aphasia), and these clinical profiles are also
consistent with MCI due to AD” (p. 272). However,
mild posterior cortical dysfunction can have a pro-
found impact on certain everyday functions (e.g.,
driving). Although comparing levels of “severity”
across different cognitive domains is difficult, it may
be that the relative impact of mild cognitive deficits
on everyday function may vary between typical and
atypical AD phenotypes.
 PCA: The second stage of progression might simply be
labeled PCA and could be entirely consistent with the
definition of PCA provided previously in classification
level I (namely fulfillment of the clinical, cognitive,
Fig. 5. Longitudinal clinical, neuropsychological, and neuroimaging profile of an individual with pathologically proven PCA-AD showing example timelines
for the provisional stages of prodromal PCA, PCA, and advanced PCA. Serial MR images (top row) show a sagittal view of the patient’s right hemisphere for all
nine visits. Repeat scans were fluid-registered to the baseline image, and color-coded voxel-compressionmaps were produced (bottom row). The scale shows the
percentage volume change per voxel (220% to 20%) with green and blue representing contraction and yellow and red representing expansion. See Kennedy
et al. [43] for a more detailed case description. Abbreviations: AD, Alzheimer’s disease; MR, magnetic resonance; PCA, posterior cortical atrophy.
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The only point of expansion is that, just as prodromal
PCA would not necessarily equate to MCI, so PCA
would not necessarily equate to dementia. Many pa-
tients with PCA for a time only show impairment in
one of the five listed domains in McKhann et al.
([19]; i.e., evidence of visuospatial but not memory,
reasoning, language, or personality/behavior deficits).
At this stage, such cases may not fulfill the various
rules for formal classification as dementia, and there-
fore diagnosis for which dementia is a prerequisite,
namely probable AD dementia, possible AD dementia,
or possible AD dementia with evidence of the AD path-
ophysiological process.
 Advanced PCA: This third provisional staging term
could be used to describe individualswhohaveorwould
have previously met criteria for PCA but in whom dis-
ease progression has led to impairments in other aspects
of cognitive function (i.e., episodic memory, language,
executive functions, behavior, and personality).
Advanced PCA might most typically be observed in
individuals in whom either (1) visual6 nonvisual pos-
terior dysfunction with relative preservation of these
other cognitive skills was the primary complaint, but
memory, language, executive, and/or behavior/person-
ality deficits have now progressed and are also signifi-
cantly impaired or (2) impairments in visual 6
nonvisual posterior functions and one or more of these
other cognitive skills were evident at presentation but
the clinical history and/or other evidence indicate thatposterior cortical deficits were the primary complaint
(i.e., the patient did not present/was not assessed at
the earlier stagewhenPCAcould have been diagnosed).
The term advanced PCAmight be applicable to a num-
ber of PCA patients described in the existing literature.
For example, in a study of PCA basic visual function
[45], all 21 patients fulfilled Mendez et al. [14] and
Tang-Wai et al. [15] criteria and had current or previous
evidence on formal neuropsychological assessment of
impaired visual function with relatively preserved
(normal range) scores on at least one test of episodic
memory. However, at the time of the experimental
study, 5/21 (24%) had progressed to a point where
episodic memory test scores fell below the normal
range, with 12/21 (57%) showing deficits on naming
from description (executive functions, behavior, and
personality were not assessed formally). The advanced
PCAconcept is particularly relevant to the characteriza-
tion of research participants, prognostic and longitudi-
nal studies, clinical management and care planning,
and for educating to patients and their caregivers.7. Heterogeneity within the PCA spectrum
Another issue that may motivate an extension of PCA ter-
minology is the challenge of describing the considerable het-
erogeneity that exists within the PCA spectrum. A number of
subtypes have been described previously based on the
distinct presentation of individuals or small series of patients
S.J. Crutch et al. / Alzheimer’s & Dementia- (2017) 1-1512(e.g., [46,47]). However, other studies have suggested that
heterogeneity in PCA is best conceptualized as a
multidimensional phenotypic space rather than as a series
of distinct subtypes (see [17,45,48–50]). The Working
Party concluded that there is currently insufficient
cognitive or neuroimaging evidence to support the
existence of discrete PCA subtypes and would recommend
research to determine whether subtypes can be found in
distinct patterns of cognitive impairment, atrophy, and
disease progression. Nonetheless, the following
provisional set of qualitative descriptions of different
positions within this putative phenotypic space is provided
to encourage debate concerning the consistent labeling
among research studies and centers and to permit
individual presentations to be described or quantified in
terms of proximity to one or more of these prototypes.
 Biparietal (dorsal) variant: This subtype has been
described as “a biparietal variant defined by the pres-
ence of early, predominant, and progressive difficulty
with visuospatial function, features of Gerstmann syn-
drome, of Balint syndrome, limb apraxia, or neglect”
[20]. This IWG2 designation is broadly consistent
with other definitions of a biparietal atrophy syndrome
(e.g., [29,46,47]).
 Occipitotemporal (ventral) variant: The biparietal
variant of PCA has been contrasted with a more ventral
occipitotemporal variant defined by the presence of an
early, predominant, and progressive impairment of
visuoperceptive functions or of visual identification
of objects, symbols, words, or faces’ (IWG2:
[20,29,46,47,51]). Such a category might include
descriptions of patients with a progressive perceptual
prosopagnosia (e.g., [52]).
 Primary visual (caudal) variant: Arguably even rarer
than the biparietal or occipitotemporal syndromes is
a more caudal primary visual syndrome characterized
by primary visual failure, impairment of basic percep-
tual abilities, and bilateral occipital atrophy
[29,47,53,54]. Owing to the early damage of primary
visual cortex, as contrasted with the early
involvement of association cortices seen in the
biparietal and occipitotemporal variants, PCA
patients with this primary visual variant are most
distinct clinically and phenotypically from “typical
AD.” The primary visual variant is rarely reported
and not mentioned explicitly in IWG2. However, this
lack of evidence may partly reflect less frequent
testing/recording of basic visual functions compared
with higher order object and space processing deficits
(of which patients are also naturally more likely to
complain). An analysis of basic visual functions
(form detection, form discrimination, form
coherence, motion coherence, color discrimination,
single-point localization) found impaired performance
in at least one basic visual skill in all 21 PCA patientstested, suggesting elementary visual deficits are a more
common cause of or contributor to higher order object
and space processing problems than is typically recog-
nized [45].
 Dominant parietal variant: The presentation of visual
complaints is a core feature of both the proposed
consensus and existing single-center diagnostic
criteria. However, not all PCA patients refer explicitly
to visual problems among their primary complaints
andmay present with predominant impairment of other
posterior cortical functions, such as calculation,
spelling, and praxis [7,30,55–57]. Such presentations
are most commonly associated with biparietal
atrophy with relatively greater involvement of the
dominant/left posterior cortices (see Fig. 4). In our sur-
vey, 67% of PCAWorking Party members considered
such individuals to fall within the PCA spectrum.
This position, and the duality of the current criteria
necessitating both “Prominent early disturbance of vi-
sual6 other posterior cortical functions” and presence
of a cluster of three or more cognitive deficits which
could appear “nonvisual” (e.g., acalculia, agraphia,
and apraxia), might at first glance appear inconsistent.
However, it is important to bear in mind that there is
not a one-to-one correspondence between cognitive
tests and the underlying cognitive processes. Many
apparently “nonvisual” tasks (e.g., calculation) do
make demands on visual imagery and spatial process-
ing skills. Furthermore, as noted previously, very
detailed neuropsychological testing of patients pre-
senting with focal posterior nonvisual complaints typi-
cally uncovers evidence of subtle impairments in
visual cognition (see Fig. 4). Finally, “nonvisual” pre-
sentations are one reason why the proposed criteria
stipulate the need for a constellation of deficits (three
or more cognitive features), to exclude for example
cases of selective apraxia which could have a more
anterior basis.
Naturally, there are multiple ways of classifying clinical
heterogeneity within the PCA spectrum. An alternative
way to discriminate putative subphenotypes would be to
refer exclusively to the organization of the visual system
(e.g., ventral and dorsal streams). Certain presentations
may also merit the combination of different types of descrip-
tive terminology (e.g., prodromal occipito-temporal variant
PCA). It is anticipated that descriptions of PCA variants
may be relevant to brain-behavior studies, phenotype char-
acterization work (e.g., clarifying the degree of homogenei-
ty/heterogeneity within the PCA spectrum), and
examinations of phenotype progression (e.g., establishing
the order of loss of different aspects of cortical visual pro-
cessing). Descriptions of PCA variants may also be useful
in the design and use of nonpharmacological interventions,
aids, and strategies which are geared toward helping individ-
uals with PCA cope with or ameliorate problems associated
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aid object localization but not object identification). Howev-
er, it should be stressed again that these descriptions are pre-
liminary characterizations of positions within a spectrum of
continuous variation.8. Conclusions
We have proposed a PCA classification framework with
both syndrome- and disease-level descriptions for use in a
number of different research contexts. The strong agreement
over the features which constitute the core clinico-
radiological syndrome (classification level 1) re-affirmed
the Working Party’s original aim of offering a consensus
statement refining and advocating specific uses and adapta-
tions of the term PCA rather than any wholesale alteration or
redescription of the syndrome. Accordingly, the working
party regard classification levels 2 (PCA-pure/PCA-plus)
and 3 (PCA-AD, PCA-LBD, PCA-CBD, PCA-Prion) as
extensions to rather than replacements for the previous
single-center diagnostic criteria, aimed at increasing the util-
ity and specification of the PCA concept in a variety of
research settings.
The three-level classification system provides a standard
against which clinicians, academics, reviewers, and editors
may evaluate and compare study populations and inclu-
sion/exclusion criteria across previous publications and
future studies. Although the proposed core features permit
of heterogeneity within the syndrome consistent with the
amassed clinical experience, reducing the variability be-
tween sites and studies caused by inconsistencies of termi-
nology and diagnostic criteria will benefit a variety of
future studies. Refining study populations and minimizing
clinico-pathological “noise” through both tighter diagnostic
criteria and in vivo biomarkers is particularly important in
the context of a relatively rare disorder such as PCA in which
sample sizes are often limited.
A number of challenges remain for the PCA research
field. A primary challenge is to understand sources and
drivers of phenotypic heterogeneity among individuals
with a common underlying pathology. For example, mem-
bers of the atypical AD PIA have contributed to the largest
analysis to date of genetic risk factors for PCA, yielding ev-
idence of both an altered risk profile across known AD risk
factors and possible novel loci some of which are associated
with visual system development [58]. The current proposed
consensus criteria for PCA may complement equivalent
consensus diagnostic criteria for typical amnestic AD
[19,20] and other atypical AD syndromes (e.g., lvPPA;
[59]) to improve the robustness and replicability of future
heterogeneity studies which may shed light on fundamental
mechanisms of disease progression and propagation.
Second, although the relationships between syndrome and
pathology are indubitably less complex than among, for
example, the frontotemporal dementias, the boundaries
between PCA, and related syndromes (e.g., CBS) requirefurther clarification through quantitative investigation. For
example, motor impairment (defined by asymmetrical left
upper limb rigidity) has been found in 30% of a series of
44 patients all meeting the existing clinical criteria for PCA
[60]. Visuospatial and visuoperceptual dysfunction in CBS
patients has also been shown to predict AD pathology
[30,61,62].
Third, a further practical objective is to establish a com-
mon framework for cognitive screening, neuropsychological
examination, and selection of cognitive outcome measures
for trials involving individuals with PCA. There is a partic-
ular need for clarity regarding the evaluation of episodic
memory in PCA [63]. As noted previously, memory tests
with explicit visual demands in encoding and/or retrieval
(e.g., Rey–Osterrieth figure copy) are unsuitable. Less
obvious are the more implicit visual demands of tests such
as verbal paired associate learning that often draw on mental
imagery. Two alternate forced choice recognition memory
tests for words [64] are suitable for evaluating aspects of
episodic memory in PCA. Evaluating alternative metrics
would help optimize techniques for establishing and quanti-
fying this critical distinction between PCA and typical am-
nestic AD, namely “prominent early disturbance of vision
with relatively preserved anterograde memory.”
The proposed classification framework will not resolve
these issues directly but may improve our ability to interpret
findings across studies, increase the quality of clinical trials
for AD, and provide a foundation for future collaborative
work. There is a need to validate the reliability, sensitivity,
and specificity of the proposed criteria, particularly to estab-
lish the quantitative relationships between the different
levels of classification. The classification system will also
likely require updating and revision, particularly based on
emergence of new biomarkers and clinical evidence of
PCA attributable to non-AD and mixed pathologies.Acknowledgments
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1. Systematic review: Consensus statements about pos-
terior cortical atrophy (PCA) were developed
through a detailed literature review, the formation
of an international multidisciplinary working party
which convened on four occasions and a Web-
based quantitative survey regarding symptom fre-
quency and the conceptualization of PCA.
2. Interpretation: The proposed classification framework
for PCA—the first consensus-based, multicenter
statement—is proposed to (1) improve the uniformity
of definition of the syndrome in a variety of research
settings, (2) encompass both syndrome- and disease-
level descriptions, (3) incorporate the recent devel-
opment of AD pathophysiological biomarkers, (4)
describe individuals with the PCA syndrome who are
negative for AD pathophysiological biomarkers, and
(5) define stages of syndrome severity and characterize
phenotypic heterogeneity within the PCA spectrum.
3. Future directions: The framework and terminology
may facilitate the interpretation of research data
across studies, be applicable across a broad range
of research scenarios (e.g., behavioral interventions,
pharmacological trials), and provide a foundation for
future collaborative work.
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